Paterna Biosciences
Paterna Biosciences is a preclinical biotechnology company developing in vitro spermatogenesis, a platform that grows functional human sperm from spermatogonial stem cells outside the body to address male-factor infertility affecting approximately 50% of all infertility cases.
- Company typePrivate
- Founded2024
- HeadquartersSalt Lake City, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Paterna Biosciences does
Paterna Biosciences is a preclinical biotechnology company headquartered in Salt Lake City, Utah, developing in vitro spermatogenesis (IVS), a platform that grows functional human sperm entirely outside the human body from spermatogonial stem cells. The company's core technology combines a proprietary molecular cocktail with computational biology and single-cell RNA sequencing to replicate the cellular environment of spermatogenesis in a laboratory setting. Paterna's addressable patient population includes men with non-obstructive azoospermia, poor sperm quality, and post-cancer treatment infertility — collectively representing roughly 50% of all infertility cases and an area that has had no FDA-approved pharmaceutical treatment since the introduction of ICSI in 1992.
The company reports achieving the world's first functional human sperm grown entirely in vitro and used to create human embryos, though the findings have not yet been peer-reviewed. Its single lead product is planned to be delivered as a per-procedure service priced at $5,000–$12,000, significantly below the $15,000–$30,000 cost of traditional IVF cycles, and integrated directly into existing IVF clinic workflows. The go-to-market motion is enterprise field sales targeting institutional investors today and fertility clinics, IVF centers, and academic medical centers post-FDA approval, with market entry targeted for 2029.
Paterna has raised approximately $11.4 million to date, including a $6 million oversubscribed seed round closed in October 2024 led by SpringTide Ventures and strategic investments from IVIRMA Global (part of KKR) and Mayo Clinic. A $12 million Series A round is currently open to fund preclinical development, a first-in-human clinical trial, and regulatory activities. The company is led by co-founders from the University of Utah and Huntsman Cancer Institute, including CEO Alex Pastuszak (MD, PhD), Chairman and Chief Medical Officer Jim Hotaling (MD, MS), and Chief of Scientific Advisors Brad Cairns (PhD, HHMI investigator and Royal Society fellow), supported by a CFO with prior Goldman Sachs experience and a regulatory affairs lead with four decades in the field.
Paterna Biosciences firmographics
Firmographics- Name
- Paterna Biosciences
- Legal name
- Paterna BioSciences, Inc.
- Website
- https://paternabio.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Paterna Biosciences is a preclinical biotechnology company developing in vitro spermatogenesis, a platform that grows functional human sperm from spermatogonial stem cells outside the body to address male-factor infertility affecting approximately 50% of all infertility cases.
- Ownership category
- akta.pro rank
Paterna Biosciences industry classification
Industry- Product category
- Reproductive Biotechnology / Male Infertility Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
- akta.pro secondary industries
- Male Reproductive & Sexual Medicine (Andrology) (HLAKAOAD), Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC), Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD)
Keywords
Where Paterna Biosciences is headquartered
LocationHeadquarters
- HQ city
- Salt Lake City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Paterna Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- In Vitro Spermatogenesis (IVS) Procedure: Once approved, Paterna plans to generate revenue through its in vitro spermatogenesis procedure, which would be performed in partnership with IVF clinics. The company projects pricing of $5,000 to $12,000 per procedure, significantly less than traditional IVF cycles costing $15,000 to $30,000. Revenue model is currently pre-commercial; the company is in preclinical development stage and raising Series A funding.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Projected IVS procedure cost: $5,000–$12,000 per treatment |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Paterna Biosciences product offering
Product offeringCore offering
Paterna Biosciences develops an in vitro spermatogenesis (IVS) platform that grows mature, functional human sperm entirely outside the body from a patient's own spermatogonial stem cells, using computational biology and single-cell genomics. The platform is intended to be integrated into existing IVF clinic workflows to address male-factor infertility, which accounts for approximately 50% of IVF failures, with projected procedure pricing of $5,000-$12,000.
Product overview
Paterna Biosciences offers a single unified product: the In Vitro Spermatogenesis (IVS) technology platform. This core technology enables the growth of functional human sperm entirely outside the body from a patient's own testicular stem cells. The company uses computational biology and single-cell genomics to replicate the in vivo spermatogenesis environment in a laboratory setting. The IVS platform integrates directly into existing IVF clinic workflows as a therapeutic-grade approach to male-factor infertility, addressing the approximately 50% of IVF failures attributable to male factor issues.
Differentiator
Problem solved
Functional benefit
Products and services
- In Vitro Spermatogenesis (IVS) Platform A laboratory-based platform that grows mature, functional human sperm entirely outside the body from a patient's own spermatogonial stem cells, using computational biology and a proprietary molecular cocktail to replicate the in vivo spermatogenesis environment. Intended to be performed in partnership with IVF clinics for men with non-obstructive azoospermia, severe oligospermia, or post-cancer infertility who currently have no biological path to genetic fatherhood. Projected procedure cost of $5,000-$12,000, materially below traditional IVF cycles.
Quantifiable outcome
- 50% of all IVF cycle failures are attributable to male factor infertility
- +4 more outcomes
Companies that use Paterna Biosciences
Customer profileSegments3 records
Ideal customer profiles3 records
Paterna Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Paterna Biosciences partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Huntsman Cancer Institute / University of UtahcoreMultiple co-founders (Brad Cairns as Chief Academic Officer and Professor & Chair; David Kircher, Graham Hickey as former/postdoctoral scientists; Bingqian Guo as former Scientist II) are affiliated with the Huntsman Cancer Institute at University of Utah. The company is headquartered adjacent to the University of Utah research ecosystem. Huntsman Cancer Institute provides foundational research infrastructure and scientific expertise in germline biology and chromatin regulation.
- Mayo Clinic and ASU MedTech AcceleratorcorePaterna was selected for the 2025 Mayo Clinic and ASU MedTech Accelerator's inaugural life sciences cohort (one of ten companies chosen). The intensive two-week program in Scottsdale, AZ provided strategic mentorship and collaboration opportunities. Paterna won the Disruption Award at this accelerator.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Paterna Biosciences competitors and assessment
Company assessmentDirect peers
- Gameto: Gameto is a biotechnology company using cell engineering to develop therapeutics for female reproductive health, including ovarian biology. Like Paterna, it applies stem cell and computational biology approaches to reproductive medicine, targeting a similar clinician and patient base with platform-level fertility innovations.
- INVO Bioscience: INVO Bioscience develops an intravaginal culture device (INVOcell) that enables a lower-cost, simplified IVF procedure performed within the body. Like Paterna, it is pursuing a more accessible, clinic-friendly alternative to traditional IVF workflows and targets the same cost-sensitive end of the fertility market.
- Posterity Health: Posterity Health is a male fertility clinic and digital health platform providing diagnostics and treatment for male reproductive health. It serves the same male-infertility patient segment that Paterna addresses, operating at the clinical-services layer rather than the therapeutic/biologic layer.
- Celmatix: Celmatix is a precision-medicine biotech focused on reproductive health, with a therapeutics program for conditions like endometriosis and infertility. Like Paterna, it is a venture-backed biotech developing novel therapeutics for an underserved reproductive indication using advanced biology.
- Legacy (Legacy Health): Legacy is a male fertility company offering sperm cryopreservation, analysis, and at-home testing services. It targets the same male-factor fertility customer base that Paterna's IVS procedure would address, operating upstream of clinical IVF.
Broad incumbents
- CooperSurgical: CooperSurgical (a CooperCompanies business) is a large, established provider of fertility and women's health medical devices, consumables, and IVF clinic services. It supplies nearly every major IVF clinic globally and is a natural channel partner or potential competitive counterparty to Paterna's IVS platform.
- Vitrolife: Vitrolife is a global provider of media, consumables, and devices for assisted reproductive technology (ART), serving virtually every IVF lab. Its existing clinic relationships and ART infrastructure make it a logical commercialization partner and potential acquirer of novel fertility platforms like Paterna's.
- Hamilton Thorne: Hamilton Thorne provides precision instruments, consumables, and software for the IVF, animal breeding, and reproductive science markets. Its established presence in andrology and ART labs, including sperm analysis tools, makes it a comparable adjacent incumbent with overlapping channel access.
Emerging players
- Androvia LifeSciences: Androvia LifeSciences is an emerging male fertility company developing diagnostics and therapeutics targeting sperm function and male-factor infertility. It addresses the same clinical problem space as Paterna at an earlier, more diagnostic-focused stage.
- Femasys: Femasys is a biomedical company developing minimally invasive solutions for women's health, including fertility and permanent contraception. While female-focused, it operates in the same reproductive-medicine regulatory and clinical channel ecosystem as Paterna and pursues novel device/biologic solutions in adjacent indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Paterna Biosciences social profiles
Digital presencePaterna Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Paterna Biosciences leadership team
Management profileNumber of profiles
Profiles22 records
Paterna Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Paterna Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Paterna Biosciences
What does Paterna Biosciences do?
Paterna Biosciences develops an in vitro spermatogenesis (IVS) platform that grows mature, functional human sperm entirely outside the body from a patient's own spermatogonial stem cells, using computational biology and single-cell genomics. The platform is intended to be integrated into existing IVF clinic workflows to address male-factor infertility, which accounts for approximately 50% of IVF failures, with projected procedure pricing of $5,000-$12,000.
Is Paterna Biosciences a public or private company?
Paterna Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Paterna Biosciences founded?
Paterna Biosciences was founded in 2024. It employs 11 to 50 people.
Where is Paterna Biosciences based?
Paterna Biosciences is headquartered in Salt Lake City, United States, in the North America region.
How does Paterna Biosciences make money?
One revenue line is on record: in Vitro Spermatogenesis (IVS) Procedure.
Who are Paterna Biosciences's main competitors?
Direct peers on record are Gameto, INVO Bioscience, Posterity Health, Celmatix and Legacy (Legacy Health). Broad incumbents are CooperSurgical, Vitrolife and Hamilton Thorne. Emerging players are Androvia LifeSciences and Femasys.
Does Paterna Biosciences have an API?
No public API is recorded for Paterna Biosciences.
What industry is Paterna Biosciences in?
Paterna Biosciences's product category is Reproductive Biotechnology / Male Infertility Therapeutics. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAKAOAD, Male Reproductive & Sexual Medicine (Andrology). Its NAICS code is 541714 and its SIC code is 8731.